CVS halts sale of Zantac products

CVS Pharmacy has suspended the sale of Zantac and other ranitidine products at its drugstores after the FDA flagged a possible human carcinogen in the popular heartburn drugs.

Advertisement

In a Sept. 28 statement, CVS said it made the decision “out of an abundance of caution.”

The decision to freeze sales of the drug comes as the FDA is evaluating whether small amounts of the carcinogen, N-nitrosodimethylamine, pose a risk to patients.

To date, no recall has been issued on Sanofi’s brand-name drug Zantac.

Customers who bought Zantac at CVS can return it for a refund.

Read the full article here.

More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.